Shire (LON:SHP)‘s stock had its “overweight” rating reaffirmed by stock analysts at JPMorgan Chase & Co. in a report released on Wednesday.
A number of other equities research analysts have also weighed in on the company. Citigroup restated a “buy” rating and set a GBX 5,500 ($74.59) price target on shares of Shire in a research note on Friday, January 5th. Liberum Capital lowered Shire to a “hold” rating and dropped their price target for the stock from GBX 4,200 ($56.96) to GBX 4,100 ($55.60) in a research note on Wednesday, December 20th. Deutsche Bank restated a “buy” rating on shares of Shire in a research note on Monday, December 11th. Morgan Stanley restated an “overweight” rating and set a GBX 5,700 ($77.30) price target on shares of Shire in a research note on Friday, December 1st. Finally, Societe Generale upped their target price on Shire from GBX 7,500 ($101.71) to GBX 8,000 ($108.49) and gave the company a “buy” rating in a research report on Wednesday, November 29th. Five equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. Shire presently has a consensus rating of “Buy” and a consensus target price of GBX 5,152.94 ($69.88).
Shares of Shire (LON:SHP) opened at GBX 3,642.50 ($49.40) on Wednesday. Shire has a 52 week low of GBX 3,435.50 ($46.59) and a 52 week high of GBX 5,067 ($68.71). The firm has a market capitalization of $33,270.00 and a PE ratio of 2,780.53.
In related news, insider Dominic Blakemore purchased 165 shares of the firm’s stock in a transaction on Tuesday, December 19th. The stock was bought at an average cost of GBX 3,790 ($51.40) per share, with a total value of £6,253.50 ($8,480.47).
ILLEGAL ACTIVITY NOTICE: “Shire (SHP) Stock Rating Reaffirmed by JPMorgan Chase & Co.” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.dispatchtribunal.com/2018/01/12/shire-shp-stock-rating-reaffirmed-by-jpmorgan-chase-co.html.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.